Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 is a rare genetic condition that mainly affects eye movement. People with this condition develop slowly worsening weakness of the eye muscles and drooping eyelids, and some also have exercise intolerance or muscle weakness in the limbs. Signs usually begin in adolescence or adulthood and tend to progress over years to decades. It is lifelong, and most people have a normal life span, but severity can vary. Treatment focuses on managing symptoms, such as eyelid surgery for ptosis, prism glasses, lubricating drops, and tailored exercise and supportive care.
Overview
Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2Symptoms
Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 causes droopy eyelids and progressively limited eye movement. Early signs include exercise intolerance and muscle weakness. Some develop swallowing trouble, fatigue, or hearing loss; heart rhythm problems are less common.
Outlook and prognosis
Many people with autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 notice slowly worsening eyelid drooping and limited eye movement over years. Vision itself often stays clear, and life expectancy is usually near typical. Regular follow-up helps manage fatigue, muscle weakness, and eye comfort.
Causes and risk factors
Caused by autosomal dominant variants in nuclear genes maintaining mitochondrial DNA, leading to multiple deletions; some cases are new mutations. Family history is the key risk. Age, intercurrent illness, smoking, alcohol, and mitochondria‑toxic medicines may worsen severity.
Genetic influences
Genetics play a central role in Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2. A single altered nuclear gene, inherited in an autosomal dominant pattern, drives large deletions in mitochondrial DNA. Variants influence age at onset, severity, and which muscles are most affected.
Diagnosis
Diagnosis relies on clinical features plus confirmation by genetic tests showing multiple mitochondrial DNA deletions, often in muscle. Muscle biopsy and family history support the genetic diagnosis of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2.
Treatment and drugs
Treatment for autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 focuses on easing eye movement weakness, managing fatigue, and supporting overall muscle function. Care may include prism glasses, eyelid lift surgery (ptosis repair), tailored exercise, and vitamins or coenzyme Q10. Regular follow-up with neurology, ophthalmology, and cardiology helps track changes and address related features early.
Symptoms
Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 mainly affects the muscles that move your eyes and lift your eyelids, and it can involve other muscles over time. Many first notice droopy lids or a need to turn the head to follow objects because the eyes don’t move as freely. Features vary from person to person and can change over time. When people talk about early features of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2, they often mean eye-related changes plus mild muscle fatigue.
Upper lids sit lower than usual and may feel heavy, especially later in the day. Clinicians call this ptosis, which means the eyelids don’t stay open as easily. You might tip your chin up or raise your eyebrows to see better.
Eyes may not look up, down, or to the sides as easily, making you turn your head to follow words on a page or a car coming from the side. This is a hallmark of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2. It usually develops slowly over years.
When the eyes don’t move together, images can appear doubled, especially when reading or driving. Covering one eye or using special lenses can help in some situations. Rest often reduces the blur temporarily.
Working to hold the lids up or move the eyes can tire the muscles. This can lead to brow ache or a heavy, strained feeling around the eyes by evening. Taking brief breaks may help.
How people usually first notice Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2?
People often first notice autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 when the eyelids start to droop (ptosis) that slowly worsens over months to years, or when it becomes hard to look up, down, or sideways without turning the head. Some also pick up on subtle exercise intolerance or unusual fatigue, and an eye doctor may find limited eye-muscle movement before other symptoms appear; these are common first signs of autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2. In families with a known history, how AD-PEO2 is first noticed may include earlier recognition through routine exams or genetic evaluation when mild eyelid droop or eye-movement stiffness begins.
Types of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2
Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 (often shortened to adPEO with mtDNA deletions 2) is a genetic condition. It has recognized clinical variants tied to which gene is affected and how much mitochondrial DNA is deleted in muscle or other tissues. These variants share a core picture—gradual weakness of the eye muscles causing droopy eyelids and limited eye movement—but differ in when symptoms start and which other systems are involved. When people ask about types of this condition, they usually mean variants of adPEO related to specific genes or deletion patterns.
POLG-related variant
Symptoms often start in early to mid-adulthood with droopy eyelids and slowly worsening eye movement limits. Muscle fatigue with walking or climbing stairs is common, and some develop nerve problems like numbness or balance changes.
TWNK-related variant
Eyelid droop and eye movement weakness tend to be prominent and sometimes appear earlier. Some people also notice exercise intolerance and mild limb weakness, while nerve involvement is usually milder than in other variants.
RRM2B-related variant
Onset can be earlier, and systemic features like hearing loss or kidney issues may occur alongside the eye symptoms. Muscle weakness can be more widespread, sometimes affecting swallowing or breathing with progression.
POLG2-related variant
Eye symptoms are central, with gradual ptosis and limited gaze, and limb weakness may develop later. Some individuals experience sensory neuropathy or seizures, though these are less frequent.
C10orf2/Twinkle overlap
This clinical label reflects cases with features similar to TWNK mutations where multiple mitochondrial DNA deletions are seen in muscle. People often have classic eye movement weakness plus exercise intolerance, with severity varying within families.
Multiple-deletions burden
In this variant description, the focus is on the amount of mitochondrial DNA deletions seen in muscle rather than a single gene. Higher deletion burden can track with more limb weakness and fatigue, even when eye symptoms look similar to other types of adPEO.
Mild late-onset form
Some adults develop only slow drooping of the eyelids and subtle eye movement limits for years. Limb weakness is minimal, and day-to-day function remains good, representing milder types of autosomal dominant progressive external ophthalmoplegia.
Expanded neurologic form
A subset develops broader nervous system involvement over time, such as neuropathy, ataxia, or seizures. These people often carry POLG or related gene changes, and early symptoms of adPEO can be a clue to this wider pattern.
What genetics can tell you about symptoms
People with this condition often develop slowly worsening eyelid drooping and trouble moving the eyes, sometimes with mild muscle weakness, because nuclear gene variants (like POLG, SLC25A4, TWNK) cause large deletions in mitochondrial DNA. These deletions reduce cellular energy, so eye muscles tire first, and other muscles may follow.
Causes and risk factors
In autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2, a single gene change disrupts how mitochondria copy their DNA. This causes multiple deletions in mitochondrial DNA and is often inherited from a parent, with a 50% chance for each child. The main risk factors for autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 are having a parent with the condition or a new mutation that arises before birth. Genes set the stage, but environment and lifestyle often decide how the story unfolds. Smoking, heavy alcohol use, and certain medicines or toxins can stress mitochondria and may worsen severity, so review new drugs or exposures with your doctor.
Environmental and biological risk factors
To understand environmental risk factors for Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2—and the biological elements that can raise the chance of it occurring in a child—it helps to look at both types of influences. Doctors often group risks into internal (biological) and external (environmental). Most everyday exposures are not linked to causing this condition; the items below focus on rare exposures and background biology.
As fathers get older, sperm are more likely to carry new DNA copying changes. This slightly raises the chance of a new change that can lead to Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2. The absolute risk for any one pregnancy remains low.
Older eggs show a modest rise in new DNA changes, though the effect appears smaller than the paternal age effect. This could slightly increase the chance of the condition occurring for the first time in a family. Most pregnancies at older ages do not result in this condition.
Parental exposure to high-dose ionizing radiation before conception can increase DNA damage in sperm or eggs. This may raise the chance of a new change associated with Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2. Typical medical imaging uses low doses that are not linked to this outcome.
Some chemotherapy medicines and radiation therapy can temporarily harm sperm or eggs. Conception soon after such treatments may carry a higher chance of new DNA changes. Care is often taken to plan pregnancy after recovery to minimize this risk.
Genetic risk factors
Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 is typically due to a single disease-causing change in the POLG gene, which helps maintain mitochondrial DNA. This nuclear gene change leads to multiple deletions in mitochondrial DNA within muscle over time, but the change itself is inherited in an autosomal dominant way. Carrying a genetic change doesn’t guarantee the condition will appear. Genetic testing is usually considered when there’s a suggestive family history or early symptoms of Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2.
POLG gene change: A single disease-causing change in the POLG gene is the key driver of this subtype. It impairs the enzyme that copies mitochondrial DNA, leading to multiple deletions in muscle over time. Different changes can shift age of onset or severity.
Autosomal dominant inheritance: Each child of someone with the POLG change has a 50% (1 in 2) chance to inherit it. Males and females are affected and can pass it on. Family trees often show several generations with similar features.
Secondary mtDNA deletions: The mitochondrial DNA deletions are a downstream effect of the nuclear gene change. They are typically not passed down through the maternal line in this subtype. This is why the pattern is autosomal rather than mitochondrial.
Variable penetrance: Not everyone who inherits the POLG change will have the same course. Some remain mild for years, while others notice eye movement weakness later in adulthood. Risk rises with age, but timing varies widely.
De novo variants: A new POLG change can appear in someone with no family history. Siblings then have a low chance of the same change, though rare germline mosaicism can raise that risk slightly. The person with the new change can pass it to future children.
Variant-specific effects: Certain POLG changes are more often linked to external ophthalmoplegia, while others relate to different mitochondrial conditions. Labs weigh the exact DNA change, family history, and test results when judging whether a change is disease-causing. Classifications may be updated as knowledge grows.
Other genes overlap: Other nuclear genes can also cause autosomal dominant PEO with multiple mitochondrial DNA deletions, but those represent different subtypes. Comprehensive panels may check POLG alongside those genes when the picture is unclear. Results help pin down the precise genetic subtype.
Family testing: Once a disease-causing POLG change is found, targeted testing can identify relatives who carry the same change. This can be helpful when early symptoms of Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 are subtle or delayed. Knowing carrier status supports planning and timely care.
Lifestyle risk factors
Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 is not caused by lifestyle, but daily habits can influence fatigue, muscle performance, and symptom flares. Thoughtful choices can help protect limited energy reserves and reduce worsening of eyelid droop or exercise intolerance. The following focuses on how lifestyle affects Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 by targeting muscle energy demands and recovery.
All-out or sustained high-intensity efforts can trigger marked muscle fatigue and next-day weakness in mitochondrial myopathy. Keeping intensity below the threshold that provokes eyelid droop or leg heaviness helps prevent symptom flares.
Planning tasks with breaks prevents energy crashes that can worsen ptosis and limb fatigue later in the day. Using a steady, submaximal pace helps you complete more without overloading the eye and skeletal muscles.
Gentle, regular aerobic activity (like easy walking or cycling) may improve endurance by enhancing mitochondrial efficiency without overstraining eye muscles. Short, frequent sessions are usually better tolerated than long workouts.
Low-to-moderate resistance with higher repetitions can maintain strength for daily activities without provoking excessive lactate buildup. Avoid max-effort lifts that cause shaking, breath-holding, or next-day crash.
Risk prevention
Because Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 is inherited, you can’t fully prevent the condition itself. Prevention can mean both medical steps, like vaccines, and lifestyle steps, like exercise. The focus is lowering complications, spotting changes early, and protecting muscle and eye function over time. Regular check-ins with clinicians who know mitochondrial disorders help tailor prevention to your needs.
A genetics visit can explain inheritance, support family planning, and discuss testing options. This helps you understand the chance of passing on Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2.
Routine eye and eyelid checks can catch changes like drooping lids or double vision early. Tell your clinician about early symptoms of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 such as new eye fatigue, headaches from squinting, or trouble tracking objects.
Gentle, regular activity can support muscle strength and energy without overtaxing the system. Aim for low–to–moderate efforts like walking, cycling, or water exercise, adjusted for Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2.
Plan tasks with breaks, and spread heavier activities across the day to avoid crashes. Avoid extreme heat and overexertion, which can worsen fatigue in this condition.
Transmission
Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 is not contagious—you can’t catch it from someone else. It follows an autosomal dominant pattern, meaning a parent living with this condition has a 50% chance with each pregnancy of passing on the gene change, regardless of the child’s sex.
The genetic transmission of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 comes from a change in a nuclear gene that secondarily leads to mitochondrial DNA deletions; the mitochondrial part does not make it “maternally inherited.” Sometimes the gene change happens for the first time in a family (a new, or de novo, variant), so there may be no prior family history. Even within the same family, the features can vary among relatives who inherit the same change.
When to test your genes
Consider genetic testing if you or close relatives have progressive eyelid drooping, limited eye movements, exercise intolerance, or early muscle weakness—especially if symptoms begin in youth or mid‑adulthood. Test sooner if there’s a family history of similar features or unexplained mitochondrial disease. Testing can guide surveillance, medications to avoid, and family planning.
Diagnosis
Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 is usually recognized when droopy eyelids and limited eye movements slowly progress over years. Doctors usually begin with a careful exam and family history, then confirm the cause with targeted tests. Because changes in mitochondrial DNA are often easier to find in muscle than in blood, some people need testing of a small muscle sample. Some diagnoses are clear after a single visit, while others take more time.
A neurologic and eye exam looks for progressive droopy eyelids (ptosis), reduced eye movement in all directions, and mild limb weakness. These features help distinguish a mitochondrial myopathy from nerve or brain causes.
An eye specialist measures eye movement range and eyelid position and checks for double vision. This helps separate PEO from conditions like myasthenia that can look similar at first.
A detailed family and health history can help show an autosomal dominant pattern across generations. Similar symptoms in a parent or close relative raise the likelihood of a hereditary form.
Basic labs may include creatine kinase (CK), thyroid studies, and lactate. These help rule out common mimics and gauge muscle involvement.
Stages of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2
Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 does not have defined progression stages. Symptoms often change slowly and vary from person to person, so eye drooping, limited eye movement, and muscle fatigue are tracked over time rather than grouped into fixed steps. Different tests may be suggested to help confirm the diagnosis, including an eye and muscle exam, blood work, and sometimes a muscle biopsy or imaging; genetic testing can look for the nuclear gene changes linked to multiple mitochondrial DNA deletions. If you’re noticing early symptoms of autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2—like persistent eyelid drooping or trouble moving the eyes—clinicians usually combine your history with targeted tests to monitor changes and guide care.
Outlook and prognosis
Changes in day-to-day life with Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 (often shortened to adPEO) usually start slowly—more effort to keep the eyelids open by late afternoon, or needing to turn your head rather than move your eyes to glance sideways. Many people find that symptoms progress over years, not weeks, and remain mainly focused on the eye muscles and droopy eyelids. Everyone’s journey looks a little different.
Doctors call this the prognosis—a medical word for likely outcomes. For many living with adPEO, the long-term outlook is compatible with a normal lifespan, especially when symptoms stay confined to the eye and eyelid muscles. Some people notice mild limb fatigue or exercise intolerance, while others continue their usual routines with small adjustments like scheduled rest and brighter task lighting. Early symptoms of adPEO can be subtle, so periodic eye and neuromuscular checkups help track changes and keep vision function as strong as possible.
A smaller group develops additional issues linked to mitochondrial energy use, such as swallowing difficulty, heart rhythm changes, or muscle weakness beyond the eyes; these features raise risks and call for closer monitoring. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, so heart screening, tailored exercise, and managing sleep and nutrition can make a meaningful difference. When rhythm problems or severe weakness occur, timely treatment reduces complications and supports independence. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 tends to unfold slowly over many years. Early symptoms of autosomal dominant progressive external ophthalmoplegia often include drooping eyelids and limited eye movement, then spread gradually to other muscles. Long-term effects vary widely, and not everyone will experience the same mix or severity of features. Most people remain independent for many years, though added fatigue and muscle weakness can shape daily routines.
Stiff or weak eye muscles make it hard to look up, down, or sideways. People may turn their head instead of moving their eyes. Vision itself is usually clear.
One or both eyelids slowly sag over time. This can narrow the field of view and cause forehead strain from trying to lift the brows.
Muscles tire early during activity, even with light tasks. Recovery can take longer than expected after exertion.
Hips and shoulders may feel weak, making stairs or lifting harder. Walking long distances can become slower and more effortful.
How is it to live with Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2?
Life with autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions (PEO) often means slowly increasing eyelid droop and limited eye movement, which can make reading, driving at night, and recognizing faces across a room harder than before. Many notice eye fatigue by afternoon and may tilt the head or raise brows to compensate, and some develop mild exercise intolerance or limb weakness that makes stairs or carrying groceries more tiring than expected. Daily routines adapt—frequent breaks for visual tasks, good lighting, and sometimes eyelid surgery or special glasses—while family, friends, and coworkers learn that slower eye tracking or a fixed gaze is part of the condition, not disinterest. With planning, honest communication, and regular medical follow‑up, most people maintain independence and stay engaged in work, school, and relationships.
Treatment and drugs
Treatment for autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 focuses on easing symptoms, protecting eye health, and supporting overall energy and muscle function. There’s no single cure, but options often include prism glasses for double vision, eyelid lift surgery (ptosis repair) when drooping limits vision, and lubricating drops or ointments to prevent dry, irritated eyes. Some specialists consider “mitochondrial cocktails” (such as coenzyme Q10, riboflavin, and L‑carnitine) to support cell energy, though benefits vary and evidence is mixed. Alongside medical treatment, lifestyle choices play a role, including balanced nutrition, paced activity with rest breaks, and tailored physical therapy to maintain strength without overexertion. Ask your doctor about the best starting point for you, and about screening for heart rhythm or muscle involvement if symptoms spread beyond the eyes.
Non-drug treatment
Droopy eyelids, eye strain, and neck fatigue from tipping your head to see can make everyday tasks harder. Early symptoms of autosomal dominant progressive external ophthalmoplegia often include eyelid droop and trouble moving the eyes together, which can lead to double vision. Alongside medicines, non-drug therapies can support your vision, comfort, and safety at home and work. Your care plan is usually tailored to your goals and may change over time as needs shift.
Thin prisms in your spectacles can join double images into one. They are adjusted to your exact pattern of double vision and can be changed as it shifts.
A small bar attached to the frame lifts droopy lids to widen your field of view. This can ease reading, computer work, and driving in daylight for people with PEO.
Skin-safe tape can gently support the upper lids during key tasks. It’s a temporary option for short activities or when you’re waiting for other treatments.
Surgical lifting of the lids can improve vision and reduce neck strain. In PEO, careful technique is needed to avoid incomplete eye closure and dryness afterward.
Your genes may have an impact on how drugs work for you
Some medicines work differently in people with autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 because genetic changes can alter how cells make energy and handle drug stress. Doctors may adjust drug choice or dose to avoid mitochondrial strain and side effects.
Pharmacological treatments
Living with this condition often means managing droopy eyelids, eye-movement limits, and muscle fatigue during everyday tasks like reading, driving, or climbing stairs. Medicines mainly aim to ease symptoms and support energy use in muscle cells; none are proven to reverse the underlying mitochondrial changes. Early symptoms of Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 often include eyelid droop (ptosis) and exercise intolerance, so treatments focus on comfort, stamina, and safety. Not everyone responds to the same medication in the same way.
May support cellular energy and reduce fatigue or exercise intolerance in some people. Benefits vary and can take weeks to notice.
An antioxidant similar to CoQ10 that may help muscle endurance in select cases. Side effects are usually mild but can include stomach upset.
Supports mitochondrial enzymes and may slightly improve energy and tolerance for activity. Often used as part of a mitochondrial supplement plan.
May assist energy pathways in muscle; some people report modest fatigue relief. Generally well tolerated at standard doses.
Genetic influences
Changes in certain nuclear genes that help copy and repair mitochondrial DNA can lead to multiple deletions in the mitochondria, lowering energy supply in muscle cells—especially those that move the eyes and lift the lids. Family history is one of the strongest clues to a genetic influence. In this autosomal dominant condition, the risk of passing Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 to a child is 1 in 2 (50%) if a parent carries the gene change. Severity and the age when symptoms first appear can vary widely within the same family, and some relatives may be very mildly affected or not notice problems until later in adulthood. A new (de novo) gene change can also occur in someone with no prior family history, but once present, it can be passed on. Genetic counseling and testing can clarify your family’s risk and help guide planning.
Is Autosomal dominant progressive external ophthalmoplegia with mitochondrial dna deletions 2 genetic?
Genetics play a central role in Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2. A single altered nuclear gene, inherited in an autosomal dominant pattern, drives large deletions in mitochondrial DNA. Variants influence age at onset, severity, and which muscles are most affected.
Pharmacogenetics—how genetics influence drug effects
For people living with Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2, the underlying gene change that affects the cell’s energy supply can also influence which medicines are safest and how well they work. Genetic testing can sometimes identify how your body handles certain medicines, helping doctors tailor dosing or choose safer options. Because mitochondria are already under strain, your team may avoid or use extra monitoring with medicines known to stress them—such as certain antibiotics (like linezolid), long propofol infusions in intensive care, and sometimes metformin in those with a history of lactic acidosis. Drug choices can also vary by the exact gene; for example, in POLG-related conditions, valproate is generally avoided because it can trigger severe liver and brain complications. Many living with Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 will have a personalized plan; doctors may discuss medications to avoid with Autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 and consider supplements like coenzyme Q10 to support energy production. Before surgery, anesthesia plans are often adjusted to limit mitochondrial stress and to watch for muscle fatigue or breathing issues afterward.
Interactions with other conditions
Living with this condition, other health issues can change how eye and muscle symptoms show up day to day. Doctors call it a “comorbidity” when two conditions occur together. Thyroid problems, diabetes, and heart rhythm issues can occur alongside autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2, and they may add to fatigue, droopy lids, or exercise intolerance. Nerve problems in the feet and hands, hearing changes, or features that resemble Parkinson’s disease sometimes overlap, while myasthenia gravis can look similar and, if also present, can make double vision and eyelid droop worse. Infections or poorly controlled sleep apnea can temporarily drain energy further, so what feels like early symptoms of autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 may actually reflect another condition flaring. Talk with your doctor about how your conditions may influence each other, especially when planning care with cardiology, neurology, and endocrinology teams.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described drooping eyelids that ran in families and slowly worsened with age, often without a clear cause. In some families, relatives remembered a grandparent who tilted the head back to see better, then a parent who did the same in midlife. Doctors noted the outward signs—heavy lids and limited eye movement—but for a long time, the reason behind them remained a mystery.
First described in the medical literature as a slowly progressive weakness of the eye muscles, the condition was initially grouped with other disorders that affect nerves and muscles. Over time, descriptions became more precise as clinicians realized that many people with progressive external ophthalmoplegia also had features pointing to an energy problem inside cells rather than a nerve issue alone. Muscle biopsies in the late 20th century showed telltale changes under the microscope, and this shifted thinking toward the tiny power units inside cells.
In recent decades, knowledge has built on a long tradition of observation. Researchers linked some families’ symptoms to changes in mitochondrial DNA inside muscle cells, and later discovered that faults in certain nuclear genes—passed down in an autosomal dominant pattern—could lead to multiple deletions in mitochondrial DNA. This explained why the condition could appear in each generation and why eye muscles, which use a lot of energy, were especially affected. The recognition of autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions 2 grew from these genetic breakthroughs and careful family studies.
Advances in genetics made testing possible, allowing clinicians to confirm the diagnosis without relying only on appearance and biopsy. Once considered rare, now recognized as part of a broader group of mitochondrial disorders, the condition’s boundaries became clearer. This helped separate it from look-alike conditions and guided counseling about inheritance, including why some relatives might have milder or later-onset symptoms.
Understanding the history of this condition also shows how science adapts. Early reports focused on drooping eyelids and limited eye movement. Later, doctors documented additional features in some people, such as mild muscle fatigue or exercise intolerance, which supported the energy shortage idea. Despite evolving definitions, the core story remained: a gradual, often family-linked weakening of the muscles that move the eyes, explained by changes in the way cells manage their energy.